A Consensus on Opioid Prescription for Oncologic Patients in Latin America - A DELPHI Study.

NCT04844788 | Unknown DMC

• 1 other identifier: 08042021
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

As seen worldwide, cancer incidence is increasing in Latin America achieving an amount of 1.3 million new cases annually.1 In addition, it is expected that up to 70% of patients with cancer will experience pain2, one of the most distressing symptoms in patients with advanced cancer. And despite of advances in cancer therapies, opioids remain the mainstay treatment of cancer-related moderate-to-severe and end-of-life pain.3 However, concerns regarding opioid prescriptions have emerged for reasons like the risk of misuse and the possibility of cancer progression. In the last decades, an increase in consumption of opioids as well as in opioids-related deaths generating the so called 'opioid crisis'. This rise is mainly due to abuse / addiction of opioids. Consequently, oncologic patients are at risk for abuse, as well as for aberrant use, which can complicate the course of cancer treatment.4 5 Another feature of opioids use in cancer patients is that it may contribute to disease progression. Experimental studies suggest that opioids can may lead to immunosuppression and tumor progression or recurrence.6-8 On the other hand, retrospective analysis of clinical data shows conflicting results and trials are lacking.

Conditions

Cancer Patients; Cancer-related Pain

Keywords

opioids; cancer-related pain; end-of-life; opioid abuse

Outcome Measures

Primary Outcomes (1)

• Survey answers

  answers of the survey sent

  Up to 3 (three) months

Eligibility Criteria

• Age: 30 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The experts assessed in this study will be the heads of anesthesia, pain management and palliative care of leading cancer hospitals of Latin America countries. For each Latin America country will be assessed 3 experts maximum.

You may qualify if:

• Head of anesthesia, Pain management and palliative care departments of cancer hospitals in Latin America.

You may not qualify if:

• Surveys not answered.

Sponsors & Collaborators

• Instituto do Cancer do Estado de São Paulo: lead

Study Sites (1)

Felipe Porto Rangel

São Paulo, São Paulo, 05409-010, Brazil

Location

MeSH Terms

Conditions

Cancer Pain; Death; Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Pathologic Processes; Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Felipe P Rangel, PhD

  MD Anderson

  PRINCIPAL INVESTIGATOR

• Juan P Cata, PhD

  M.D. Anderson Cancer Center

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: April 9, 2021
• First Posted: April 14, 2021
• Study Start: April 15, 2021
• Primary Completion: May 30, 2021
• Study Completion: June 30, 2021
• Last Updated: April 14, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

BR (1)